This week, the U.S. government named 10 drugs that will be subject to the first ever price negotiations by Medicare. WSJ’s Jared Hopkins talks about how this major change came about and pharmaceutical companies’ efforts to stop it.
Further Listening:
-How Big Pharma Lost Its Swagger
Further Reading:
-Expensive Drugs From Pfizer, Other Companies Targeted for First U.S. Price Negotiations
-U.S. Chamber of Commerce Challenges Federal Government’s New Drug-Price Powers
-Merck Challenges U.S. Government’s New Powers to Negotiate Drug Prices
Where to Listen
